«The progression of Parkinson’s disease varies among different individuals, it is chronic and slowly progressive, with symptoms continuing and worsening over a period of years.»
Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. An estimated seven to ten million people suffer from the disease worldwide. The combined direct and indirect cost including treatment, social security payments and lost income from inability to work, is estimated to be nearly US$ 25 billion per year in the United States alone.
There are several medications available to treat the symptoms of Parkinson’s, although none that can actually address the progressive neurodegeneration that is the underlying cause of the disease.
Neurimmune’s antibody program for Parkinson's disease targets neuropathological aggregates of the alpha-synuclein protein that are believed to be a key driver of the neurodegeneration in Parkinson's and related neurological disorders. This program was exclusively partnered with Biogen in 2010 and is currently in Phase 1 clinical trials.